Mostrar el registro sencillo del ítem
The use of vitamins and coenzyme Q10 for the treatment of vascular occlusion diseases affecting the retina
dc.contributor.author | Fernández-Vega B. | |
dc.contributor.author | Nicieza J. | |
dc.contributor.author | Álvarez-Barrios A. | |
dc.contributor.author | Álvarez L. | |
dc.contributor.author | García M. | |
dc.contributor.author | Fernández-Vega C. | |
dc.contributor.author | Vega J.A. | |
dc.contributor.author | González-Iglesias H. | |
dc.date.accessioned | 2020-09-02T22:17:32Z | |
dc.date.available | 2020-09-02T22:17:32Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.3390/nu12030723 | |
dc.identifier.citation | 12, 3, - | |
dc.identifier.issn | 20726643 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/4464 | |
dc.description | Nutritional supplementation with antioxidants and vitamins is widely recommended in the treatment of vascular disorders affecting the retina, although there is insufficient evidence on its effectiveness. The vitamin-like compound coenzyme Q10 (CoQ10) is a nutritional supplement of current interest to treat neurodegenerative diseases. Here, we report a retrospective clinical case series study of 48 patients diagnosed with retinal vascular diseases, including non-arteritic ischemic optic neuropathy (NAION), retinal artery occlusion (RAO), and homonymous hemianopia or quadrantanopia following stroke, treated with oral supplementation with CoQ10 (100 mg per day) and vitamins. Patient follow-up was performed using the Humphrey field analyzer and 30-2 testing algorithm to determine the visual field index (VFI) and progression rates. All treated patients showed positive VFI progression rates per year: +11.5 ± 15% for NAION patients (n = 18), +22 ± 17% for RAO patients (n = 7), +9.3 ± 10.5% for hemianopia/quadrantanopia patients (n = 10), and +11 ± 21% for patients with other conditions (n = 13). The interruption of CoQ10 supplementation in one patient resulted in a pronounced decrease of the VFI, which was partially recovered when treatment was restored. This study supports the role of CoQ10 as a nutritional therapeutic agent for vascular diseases affecting the retina. Owing to decreased VFI after interruption of CoQ10, its beneficial effects may be reversible. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. | |
dc.language.iso | en | |
dc.publisher | MDPI AG | |
dc.subject | Coenzyme Q10 | |
dc.subject | Dietary supplementation | |
dc.subject | Retina | |
dc.subject | Vascular diseases | |
dc.subject | Visual field defects | |
dc.subject | Vitamins | |
dc.subject | ascorbic acid | |
dc.subject | cyanocobalamin | |
dc.subject | magnesium | |
dc.subject | nutrition supplement | |
dc.subject | pyridoxine | |
dc.subject | selenium | |
dc.subject | thiamine | |
dc.subject | ubidecarenone | |
dc.subject | vitamin | |
dc.subject | xanthophyll | |
dc.subject | zeaxanthin | |
dc.subject | zinc | |
dc.subject | adult | |
dc.subject | Article | |
dc.subject | clinical article | |
dc.subject | controlled study | |
dc.subject | diet supplementation | |
dc.subject | female | |
dc.subject | follow up | |
dc.subject | hemianopia | |
dc.subject | homonymous hemianopia | |
dc.subject | human | |
dc.subject | male | |
dc.subject | middle aged | |
dc.subject | optic nerve | |
dc.subject | optic nerve atrophy | |
dc.subject | optical coherence tomography | |
dc.subject | retina | |
dc.subject | retina artery | |
dc.subject | retina blood vessel occlusion | |
dc.subject | vascular disease | |
dc.subject | vision | |
dc.subject | visual evoked potential | |
dc.subject | visual field | |
dc.subject | vitamin supplementation | |
dc.title | The use of vitamins and coenzyme Q10 for the treatment of vascular occlusion diseases affecting the retina | |
dc.type | Article |